vs
Side-by-side financial comparison of VICOR CORP (VICR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
VICOR CORP is the larger business by last-quarter revenue ($113.0M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). VICOR CORP runs the higher net margin — 18.3% vs -49.0%, a 67.3% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 20.2%).
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
VICR vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.0M | $70.6M |
| Net Profit | $20.7M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 59.7% | -56.7% |
| Net Margin | 18.3% | -49.0% |
| Revenue YoY | 20.2% | 81958.1% |
| Net Profit YoY | 713.9% | 54.9% |
| EPS (diluted) | $0.44 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $113.0M | — | ||
| Q4 25 | $107.3M | — | ||
| Q3 25 | $110.4M | $70.6M | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $94.0M | — | ||
| Q4 24 | $96.2M | — | ||
| Q3 24 | $93.2M | — | ||
| Q2 24 | $85.9M | — |
| Q1 26 | $20.7M | — | ||
| Q4 25 | $46.5M | — | ||
| Q3 25 | $28.3M | $-34.6M | ||
| Q2 25 | $41.2M | — | ||
| Q1 25 | $2.5M | — | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $-1.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | 55.4% | — | ||
| Q3 25 | 57.5% | — | ||
| Q2 25 | 95.9% | — | ||
| Q1 25 | 47.2% | — | ||
| Q4 24 | 52.4% | — | ||
| Q3 24 | 49.1% | — | ||
| Q2 24 | 49.8% | — |
| Q1 26 | 59.7% | — | ||
| Q4 25 | 14.6% | — | ||
| Q3 25 | 18.9% | -56.7% | ||
| Q2 25 | 47.3% | — | ||
| Q1 25 | -0.2% | — | ||
| Q4 24 | 9.6% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 0.2% | — |
| Q1 26 | 18.3% | — | ||
| Q4 25 | 43.4% | — | ||
| Q3 25 | 25.6% | -49.0% | ||
| Q2 25 | 42.9% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | -1.4% | — |
| Q1 26 | $0.44 | — | ||
| Q4 25 | $1.01 | — | ||
| Q3 25 | $0.63 | — | ||
| Q2 25 | $0.91 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $0.26 | — | ||
| Q2 24 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $754.1M | $503.0M |
| Total Assets | $804.9M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $404.2M | — | ||
| Q4 25 | $402.8M | — | ||
| Q3 25 | $362.4M | $490.9M | ||
| Q2 25 | $338.5M | — | ||
| Q1 25 | $296.1M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $267.6M | — | ||
| Q2 24 | $251.9M | — |
| Q1 26 | $754.1M | — | ||
| Q4 25 | $711.6M | — | ||
| Q3 25 | $630.1M | $503.0M | ||
| Q2 25 | $608.6M | — | ||
| Q1 25 | $580.3M | — | ||
| Q4 24 | $570.1M | — | ||
| Q3 24 | $554.6M | — | ||
| Q2 24 | $537.2M | — |
| Q1 26 | $804.9M | — | ||
| Q4 25 | $785.8M | — | ||
| Q3 25 | $710.2M | $577.1M | ||
| Q2 25 | $693.5M | — | ||
| Q1 25 | $665.0M | — | ||
| Q4 24 | $641.1M | — | ||
| Q3 24 | $632.8M | — | ||
| Q2 24 | $613.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $15.7M | — | ||
| Q3 25 | $38.5M | $-84.6M | ||
| Q2 25 | $65.2M | — | ||
| Q1 25 | $20.1M | — | ||
| Q4 24 | $10.1M | — | ||
| Q3 24 | $22.6M | — | ||
| Q2 24 | $15.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | $10.2M | — | ||
| Q3 25 | $34.5M | $-84.7M | ||
| Q2 25 | $59.0M | — | ||
| Q1 25 | $15.6M | — | ||
| Q4 24 | $8.4M | — | ||
| Q3 24 | $14.1M | — | ||
| Q2 24 | $9.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 9.5% | — | ||
| Q3 25 | 31.2% | -120.1% | ||
| Q2 25 | 61.5% | — | ||
| Q1 25 | 16.6% | — | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | 15.2% | — | ||
| Q2 24 | 11.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 5.2% | — | ||
| Q3 25 | 3.6% | 0.2% | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 9.1% | — | ||
| Q2 24 | 7.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 7.93× | — | ||
| Q4 24 | 0.99× | — | ||
| Q3 24 | 1.95× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
VRDN
Segment breakdown not available.
